Experienced life sciences development team and distinguished scientists with a track record of success
Our Commitment to Data-driven Science
First to discover
A novel, narrow-spectrum drug that kills Borrelia burgdorferi with limited impact on healthy gut microbiome
A single, targeted-formulation of an approved drug that kills co-infectious bacteria in Lyme disease and limits microbiome damage
A distinct microbiome signature with potential to become the first diagnostic for patients with chronic Lyme disease